Trials
Search / Trial NCT06438705

99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors

Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · May 31, 2024

Trial Information

Current as of February 18, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique that uses a special probe to help doctors see tumors more clearly. The probe is designed to target a specific protein found in certain cancers, including head and neck tumors, lung cancer, and pancreatic cancer. By improving how we visualize these tumors, the researchers hope to enhance early diagnosis and treatment options for patients.

To participate in the trial, volunteers need to be between 18 and 75 years old and have been diagnosed with a tumor that can be seen using other imaging methods. They should also be in good health overall, with specific kidney and blood test results meeting certain criteria. Participants will receive the new imaging probe, and the study will monitor its safety and effectiveness. It's important to know that individuals with severe allergies, certain health conditions, or those who are pregnant or breastfeeding cannot join the trial. This research could lead to better ways to detect and treat cancers, potentially improving outcomes for many patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Voluntary subjects, patients or their legal representatives sign informed consent;
  • Volunteers are of any gender and aged between 18 and 75 years old, including the cut-off value;
  • Other imaging methods found tumor occupying;
  • Patients with pre-treatment tumors for whom surgery or biopsy may be performed to obtain final pathological results.
  • Kidney glomerular filtration rate(GFR)\>50 ml/min, effective renal plasma flow(ERPF)\>280 ml/min, platelet count (PLT) \>75 000/μL, white blood cell (WBC) \>3000/μL, alanine aminotransferase ALT, aspartate aminotransferase AST less than 3 times the normal value.
  • Exclusion Criteria:
  • People who have a history of allergy to similar drugs , allergic constitution or are currently suffering from allergic diseases;
  • Is conducting clinical research on other drugs, or has participated in clinical research on any drugs (excluding vitamins and minerals);
  • Have other clinical problems that are difficult to control (such as hepatitis C virus infection or active hepatitis B, or other serious chronic infections and serious mental, neurological, cardiovascular, respiratory and other diseases);
  • Obvious abnormal liver and kidney function, GFR less than 50 ml/min;
  • Tumor load is greater than 50%, or there is obvious spinal cord compression;
  • The expected survival period is less than half a year; Chemotherapy was performed within 6 months.
  • Have severe acute concomitant diseases or serious refractory mental disorders;
  • Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy study);
  • Patients whose physical condition is not suitable for radiological examination;
  • Other situations deemed inappropriate by the investigator to participate in the trial.

About Nanjing First Hospital, Nanjing Medical University

Nanjing First Hospital, affiliated with Nanjing Medical University, is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care and cutting-edge medical practices, the hospital serves as a key player in the development of new therapies and treatment protocols. Its collaborative environment fosters interdisciplinary research, enabling the integration of scientific inquiry with clinical application. Nanjing First Hospital is committed to improving health outcomes and contributing to the global medical community through rigorous trial design and execution, ensuring the highest standards of ethical practice and patient safety.

Locations

Nanjing, Jiangsu, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0